Synlogic Announces Contract with the Air Force Research Lab
- None.
- None.
Insights
The subcontract awarded to Synlogic by the Air Force Research Lab signifies an acknowledgment of the company's proficiency in synthetic biology and its applications in developing biotherapeutics. The financial injection is geared towards advancing a manufacturing process for a live probiotic product, which is a niche area within the biotech sector. The commitment of resources to this endeavor reflects confidence in Synlogic's capabilities and the potential market for probiotics in healthcare.
Probiotics, particularly those engineered for specific health outcomes, are an emerging field. The development of such products could lead to significant advancements in managing various diseases, potentially reducing healthcare costs and improving patient outcomes. The impact on Synlogic's business could be substantial if the product reaches commercialization, as it would diversify their portfolio and possibly create a new revenue stream. However, this is contingent on successful development and subsequent regulatory approvals, which are inherently uncertain in the biotechnology industry.
The announcement of Synlogic's involvement in the AFRL project could influence investor perceptions, particularly as it pertains to the company's strategic positioning in the biotech market. While the contract value of approximately $1 million may not be substantial relative to the overall financials of larger biotech firms, for a clinical-stage company like Synlogic, it represents both a financial boost and a validation of their technological capabilities.
Investors will likely monitor the progress of this project closely, as successful execution could enhance Synlogic's reputation for innovation and potentially attract further partnerships. Additionally, the timeline of the project, spanning a year, provides a clear checkpoint for stakeholders to assess progress. It is important to note, however, that the actual impact on the stock market will depend on broader market conditions and investor sentiment towards risk in the biotech sector.
Developing a manufacturing process for live probiotic products presents unique challenges, including ensuring viability and stability of the organisms throughout the production cycle. Synlogic's expertise in synthetic biology could offer innovative solutions to these challenges, such as optimizing growth conditions or engineering probiotics for increased resilience. The success of this process development will be critical not only for the current project but also for setting a precedent in the field of live biotherapeutic production.
It is essential to consider the scalability of the manufacturing process being developed. The ability to produce at larger scales without compromising product quality is crucial for commercial viability. As the project progresses, Synlogic's approach to addressing these technical aspects will be of great interest to industry observers and could influence future practices in biomanufacturing.
- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately
The grant is an extension of work initiated by Synlogic in 2020 as part of the Air Force Synthetic Biology Challenge with the Massachusetts Institute of Technology (MIT).
Synlogic’s activities on this project are expected to start in Q1 2024 and will be complete in Q1 2025.
About The Air Force Research Laboratory (AFRL)
The Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space, and cyberspace force. With a workforce of more than 12,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit: www.afresearchlab.com.
About Synlogic
Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit www.synlogictx.com or follow us on Twitter, LinkedIn, Facebook or Instagram.
Forward Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "look forward, " "estimate," "expect," “focused on,” "intend," "on track, " "plan," "predict" and similar expressions and their variants, as they relate to Synlogic, may identify forward-looking statements. Examples of forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's approach to Synthetic Biotics to develop therapeutics to address a wide range of diseases including: inborn errors of metabolism and inflammatory and immune disorders; our expectations about sufficiency of our existing cash balance; the future clinical development of Synthetic Biotics; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials of labafenogene marselecobac (previously known as SYNB1934), SYNB1353, SYNB8802 and SYNB2081 and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statements as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading "Risk Factors" in Synlogic's filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
Media Contact: media@synlogictx.com
Investor Relations: investor@synlogictx.com
FAQ
What is the latest announcement from Synlogic, Inc. (Nasdaq: SYBX)?
What is the purpose of the subcontract secured by Synlogic, Inc. (Nasdaq: SYBX)?
When are Synlogic's activities on this project expected to start and end?
What was the previous work initiated by Synlogic, Inc. (Nasdaq: SYBX) in 2020?
